Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) is a cell surface transmembrane metalloprotease with a key role in cleaving and releasing the extracellular domains of numerous membrane proteins, including cytokine precursors, cell adhesion molecules, and signaling receptors. It is critical for the proteolytic processing of Notch, amyloid precursor protein (as alpha-secretase), and other substrates important in neural development, immune modulation, and vascular biology. ADAM10 is implicated in multiple diseases, such as cancer, Alzheimer disease, inflammation, and autoimmune disorders, and is under investigation as a therapeutic target, though no drugs specifically targeting ADAM10 are approved for clinical use.
Inhibition of proteolytic cleavage of substrates (e.g., Notch receptor, amyloid precursor protein, cytokine receptors); Modulation of signaling pathways via altered shedding of cell surface molecules
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10).